癌症患者中因子 XIII 活性和单核细胞衍生微粒的临床意义
Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients.
作者信息
Sawai Yusuke, Yamanaka Yuta, Nomura Shosaku
机构信息
First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
出版信息
Vasc Health Risk Manag. 2020 Apr 1;16:103-110. doi: 10.2147/VHRM.S240500. eCollection 2020.
BACKGROUND
The aim was to evaluate factor XIII activity (FXIIIa) and monocyte-derived microparticles (MDMPs) in cancer patients.
METHODS
In total, 138 cancer patients (31 malignant lymphomas, 39 multiple myelomas, and 68 lung cancers) were analyzed. We measured various biomarkers including FXIIIa and MDMPs.
RESULTS
The values of endothelial activation markers, monocyte chemoattractant peptide (MCP)-1, soluble (s)CD14, and MDMPs were higher in cancer patients than in non-cancerous controls. MCP-1, sCD14, and MDMPs were significantly correlated with FXIIIa in multivariate analysis in cancer patients. In addition, MCP-1, sCD14, and MDMP levels were significantly increased in the high FXIIIa group of patients. Finally, the survival rate of the high FXIIIa group was significantly poor in the Kaplan-Meier analysis.
CONCLUSION
These results suggest that abnormal levels of FXIIIa and MDMPs may offer promise as poor prognostic factors in cancer patients.
背景
目的是评估癌症患者的凝血因子 XIII 活性（FXIIIa）和单核细胞衍生的微粒（MDMPs）。
方法
总共分析了 138 名癌症患者（31 例恶性淋巴瘤、39 例多发性骨髓瘤和 68 例肺癌）。我们测量了包括 FXIIIa 和 MDMPs 在内的各种生物标志物。
结果
癌症患者体内内皮细胞活化标志物、单核细胞趋化蛋白（MCP）-1、可溶性（s）CD14 和 MDMPs 的值高于非癌症对照。在癌症患者的多变量分析中，MCP-1、sCD14 和 MDMPs 与 FXIIIa 显著相关。此外，FXIIIa 水平高的患者组中 MCP-1、sCD14 和 MDMP 水平显著升高。最后，在 Kaplan-Meier 分析中，FXIIIa 水平高的患者组生存率显著较差。
结论
这些结果表明，FXIIIa 和 MDMPs 的异常水平可能有望作为癌症患者预后不良的因素。
Zotero 插件